OBJECTIVE: B cells play a dominant role in the pathogenesis of several autoimmune diseases, including systemic lupus erythematosus. It is not well understood how B cell signaling contributes to autoantibody production. The goal of this study was to elucidate the role of CD72 in modulating B cell receptor (BCR)-mediated tolerogenic signaling and peripheral B cell tolerance. METHODS: A mouse model utilizing hen egg lysozyme (HEL) "anergic" B cells was studied. CD72-deficient mice carrying the BCR-specific IgHEL and/or soluble HEL (sHEL) transgenes were generated by breeding IgHEL-transgenic MD4 mice and/or sHEL-transgenic ML5 mice with congenic, CD72-deficient C57BL/6J mice. Normal and anergic B cells were isolated for analyses of B cell signaling. Aged wild-type and CD72-deficient mice were also examined for autoimmune phenomena. RESULTS: In the absence of CD72, anergic B cells inappropriately proliferated and survived in response to stimulation with self antigen. Biochemical analyses indicated that in anergic B cells, CD72 dominantly down-regulated BCR signaling to limit the antigen-induced elevation in [Ca2+]i and the activation of NFATc1, NF-kappaB, MAPK, and Akt. Mechanistically, CD72 was associated with, and regulated, the molecular adaptor Cbl-b in anergic B cells, suggesting that Cbl-b may play a role in mediating the negative effects of CD72 on BCR signaling. Moreover, in aged CD72-deficient mice, spontaneous production of antinuclear and anti-double-stranded DNA autoantibodies and features of lupus-like autoimmune disease were observed. CONCLUSION: CD72 is required to maintain B cell anergy and functions as a regulator of peripheral B cell tolerance. Thus, altered CD72 expression may play a role during the development of systemic lupus erythematosus.
OBJECTIVE: B cells play a dominant role in the pathogenesis of several autoimmune diseases, including systemic lupus erythematosus. It is not well understood how B cell signaling contributes to autoantibody production. The goal of this study was to elucidate the role of CD72 in modulating B cell receptor (BCR)-mediated tolerogenic signaling and peripheral B cell tolerance. METHODS: A mouse model utilizing hen egg lysozyme (HEL) "anergic" B cells was studied. CD72-deficient mice carrying the BCR-specific IgHEL and/or soluble HEL (sHEL) transgenes were generated by breeding IgHEL-transgenic MD4 mice and/or sHEL-transgenic ML5 mice with congenic, CD72-deficient C57BL/6J mice. Normal and anergic B cells were isolated for analyses of B cell signaling. Aged wild-type and CD72-deficient mice were also examined for autoimmune phenomena. RESULTS: In the absence of CD72, anergic B cells inappropriately proliferated and survived in response to stimulation with self antigen. Biochemical analyses indicated that in anergic B cells, CD72 dominantly down-regulated BCR signaling to limit the antigen-induced elevation in [Ca2+]i and the activation of NFATc1, NF-kappaB, MAPK, and Akt. Mechanistically, CD72 was associated with, and regulated, the molecular adaptor Cbl-b in anergic B cells, suggesting that Cbl-b may play a role in mediating the negative effects of CD72 on BCR signaling. Moreover, in aged CD72-deficient mice, spontaneous production of antinuclear and anti-double-stranded DNA autoantibodies and features of lupus-like autoimmune disease were observed. CONCLUSION:CD72 is required to maintain B cell anergy and functions as a regulator of peripheral B cell tolerance. Thus, altered CD72 expression may play a role during the development of systemic lupus erythematosus.
Authors: Daniel H Li; James W Tung; Ingo H Tarner; Andrew L Snow; Tsuyoshi Yukinari; Rachel Ngernmaneepothong; Olivia M Martinez; Jane R Parnes Journal: J Immunol Date: 2006-05-01 Impact factor: 5.422
Authors: Y J Chiang; H K Kole; K Brown; M Naramura; S Fukuhara; R J Hu; I K Jang; J S Gutkind; E Shevach; H Gu Journal: Nature Date: 2000-01-13 Impact factor: 49.962
Authors: K Bachmaier; C Krawczyk; I Kozieradzki; Y Y Kong; T Sasaki; A Oliveira-dos-Santos; S Mariathasan; D Bouchard; A Wakeham; A Itie; J Le; P S Ohashi; I Sarosi; H Nishina; S Lipkowitz; J M Penninger Journal: Nature Date: 2000-01-13 Impact factor: 49.962
Authors: Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier Journal: Immunity Date: 2011-11-09 Impact factor: 31.745
Authors: D Saadoun; B Terrier; J Bannock; T Vazquez; C Massad; I Kang; F Joly; M Rosenzwajg; D Sene; P Benech; L Musset; D Klatzmann; E Meffre; P Cacoub Journal: Arthritis Rheum Date: 2013-04